UK accelerates clinical trials with new 2026 reforms
The UK is stepping up its bid to become a global leader in clinical trials, with new figures from the Medicines and Healthcare products Regulatory Agency (MHRA) revealing a sharp increase in research activity during 2025. According to the MHRA, applications for clinical trials rose by 9% between January and November 2025 compared with the same period in 2024. The strongest growth was seen in early-phase and innovative trials, critical areas where speed and regulatory guidance influence investment decisions. Trials involving healthy volunteers, often the first step in testing a medicine’s safety, increased by 16%. Studies assessing treatments in patients for the first time rose by 5%, while trials launched in the UK for the first time climbed 7%, reflecting growing international confidence in the country as a hub for new research. MHRA Chief Executive Lawrence Tallon believes the latest reforms will further amplify the UK as a hotspot for clinical research: “Clinical trial sponsors are clear about what they need: speed, clarity and flexibility. We’ve made practical improvements that are helping trials move through the system more smoothly. …



